No serious treatment-related adverse events in Rett gene therapy trials
Top-line interim data from pivotal Phase 3 trial expected in first half of 2027
Written by |
All 33 girls and young women with Rett syndrome dosed with the gene therapy TSHA-102 across clinical trials have cleared the acute safety monitoring window, with no reported serious treatment-related adverse events. (Photo from iStock)
All 33 girls and young women with Rett syndrome dosed with Taysha Gene Therapies‘ experimental gene therapy TSHA-102 across clinical trials have cleared the acute safety monitoring window, with no reported serious treatment-related adverse events or dose-limiting toxicities.
These positive safety data were drawn from 29 girls and young women, ages 5 to 21, in the ongoing Phase 1/2 and pivotal Phase 3 REVEAL trials (NCT06152237, NCT05606614), and four girls, ages 2 to 3, in the Phase 3 ASPIRE study (NCT07480564).
Top-line data from a six-month interim analysis of the pivotal Phase 3 portion of REVEAL, designed to generate definitive evidence to support a biologics license application (BLA) seeking approval of TSHA-102, is expected in the first half of 2027.
Meanwhile, following alignment with the U.S. Food and Drug Administration (FDA), the company has completed the process performance qualification (PPQ) manufacturing campaign. This is part of the validation phase of the commercial manufacturing process required before Taysha can submit a BLA and distribute a drug commercially.
“With all patients dosed and having cleared the acute post-dosing safety monitoring period in our REVEAL pivotal and ASPIRE trials …, our focus now turns to delivering a robust dataset to support our planned BLA submission and further establish the potential of TSHA-102 to address the significant unmet need in Rett syndrome,” Sean P. Nolan, chairman and CEO of Taysha, said in a company press release. “In parallel, we achieved an important manufacturing milestone with the successful completion of our BLA-enabling PPQ manufacturing campaign, which met the predefined acceptance and comparability criteria previously reviewed with FDA.”
TSHA-102 delivers healthy copy of key gene to brain cells
Taysha also plans to discuss chemistry, manufacturing and controls data, or the details of how a therapy is produced, tested, and kept consistent, with the agency. FDA feedback on this meeting is expected by the end of March 2027, and on the BLA submission pathway in the first half of 2027.
Data supporting the TSHA-102 clinical program were presented at the 55th Child Neurology Society Annual Meeting, held last month in Montreal.
Most cases of Rett are caused by changes in the MECP2 gene. TSHA-102 is a treatment that delivers a healthy copy of this gene to brain cells. It also includes built-in controls that regulate the gene’s activity so it doesn’t become overactive and cause harm. Doctors give the therapy directly into the spinal canal using a procedure called an intrathecal injection.
According to interim data from the REVEAL Phase 1/2 program, the gene therapy led to improvements in motor function, communication abilities, and social skills.
The main goal of the pivotal Phase 3 portion of REVEAL is the proportion gaining/regaining at least one of 28 developmental milestones generally not achieved in the absence of treatment. The ASPIRE study will provide at least three months of safety data for BLA inclusion to support a broad label for patients ages 2 years and older.
We believe the first half of 2027 could be a transformative period for Taysha with our plan to report data from the six-month interim analysis of our REVEAL pivotal trial along with expected FDA feedback on our BLA submission pathway.
The PPQ manufacturing campaign included production of commercial-scale drug product batches. According to the company, all process and analytical results met predefined specifications and comparability criteria for a commercial product and clinical material.
Together with the comparability of the clinical material used across the REVEAL Phase 1/2 and Phase 3 pivotal trials, these results support the potential inclusion of the Phase 1/2 data in the planned BLA submission.
In addition, the final commercial manufacturing process consistently achieved a single-digit percentage of empty capsids, the viral shells that do not contain the therapeutic gene. This measure is an indicator of product quality that contributes to patient safety, according to Taysha. The PPQ results also demonstrated the consistency and scalability of the product that are required to support commercial demand.
“We believe the first half of 2027 could be a transformative period for Taysha with our plan to report data from the six-month interim analysis of our REVEAL pivotal trial along with expected FDA feedback on our BLA submission pathway,” Nolan said.
Leave a comment
Fill in the required fields to post. Your email address will not be published.